Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: Translation of microarray data into clinically usefull predictive signatures

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Modlich, Olga ^a   Prisack, Hans Bernd ^a   Munnes, Marc ^b   Audretsch, Werner ^c   Bojar, Hans ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c City Hospital   (Germany)

Author keywords

Breast cancer; Microarray; Preoperative chemotherapy; Prognostic classification

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; GENOMIC DNA; GOSERELIN; LETROZOLE; MESSENGER RNA; TAMOXIFEN;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER TISSUE; CLASSIFICATION; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DECISION THEORY; DISEASE COURSE; DNA MICROARRAY; DRUG RESPONSE; GENE EXPRESSION; GENETIC ALGORITHM; GENETIC MARKER; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LINEAR SYSTEM; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTION; PREOPERATIVE TREATMENT; RANK SUM TEST; REGRESSION ANALYSIS; SAMPLING; STATISTICAL ANALYSIS; STATISTICAL MODEL; STUDENT T TEST; TREATMENT OUTCOME;

EID: 27344436232     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-32     Document Type: Article

References (69)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al.: Cancer statistics. CA Cancer J Clin 2004, 54:8-29.
2. Waterworth A: Introducing the concept of breast cancer stem cells. Breast Cancer Res 2004, 6:53-54.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
4. Early Breast Cancer Trialists' Collaborative Group: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1, CD000487 2002.
5. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 1, CD000486 2001.
6. Russo G, Zegar C, Giordano A: Advantages and limitations of microarray technology in human cancer. Oncogene 2003, 22:6497-6507.
7. Goldsmith ZG, Dhanasekaran N: The microrevolution: applications and impacts of microarray technology on molecular biology and medicine (review). Int J Mol Med 2004, 13:483-495.
8. Zhang W, Laborde PM, Coombes KR, Berry DA, Hamilton SR: Cancer genomics: promises and complexities. Clin Cancer Res 2001, 7:2159-2167.
9. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H: Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004, 10:6418-6431.
10. Garces CA, Cance WG: Neoadjuvant chemotherapy of breast cancer. Am Surg 2004, 70:565-569.
11. Scholl SM, Asselain B, Palangie T, Dorval T, Jouve M, Garcia Giralt E, et al.: Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991, 27:1668-1671.
12. Green M, Hortobagyi GN: Neoadjuvant chemotherapy for operable breast cancer. Oncology (Huntingt) 2002, 16:871-898.
13. Brenin DR, Morrow M: Breast-conserving surgery in the neoadjuvant setting. Semin Oncol 1998, 25(Suppl 3):13-18.
14. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-93.
15. Schwartz GF, Hortobagyi GN: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast. Cancer 2004, 100:2512-2532.
16. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990, 82:1539-1545.
17. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
18. Brittenden J, Heys SD, Miller I, Sarkar TK, Hutcheon AW, Needham G, et al.: Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study. Br J Cancer 1994, 69:918-921.
19. Chollet P, Charrier S, Brain E, Cure H, van Praagh I, Feillel V, et al.: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997, 33:862-866.
20. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, et al.: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86:1041-1046.
21. Pierga JY, Mouret E, Laurence V, Dieras V, Savigioni A, Beuzeboc P, et al.: Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response. Eur J Cancer 2003, 39:1089-1096.
22. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, et al.: Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 2002, 236:295-302.
23. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, et al.: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002, 4:3.
24. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362-369.
25. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22:2284-2293.
26. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, et al.: Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002, 8:461-468.
27. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586.
28. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, et al.: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002, 359:131-2.
29. Monfardini S, Brunner K, Crowther D: Evaluation of the cancer patient and the response to treatment. In UICC-Manual of Adult and Pediatric Medical Oncology Berlin, Germany: Spinger; 1987:22-38.
30. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al.: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996, 14:1675-1680.
31. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, et al.: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A 1999, 96:6745-6750.
32. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M: Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiol Genomics 2000, 2:143-147.
33. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al.: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10:6622-6628.
34. Cocquyt VF, Schelfhout VR, Blondeel PN, Depypere HAT, Daems KK, Serreyn RF, et al.: The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer. Med Oncol 2003, 20:221-231.
35. Takei H, Horiguchi J, Maemura M, Koibuchi Y, Oyama T, Yokoe T, et al.: Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy. Oncol Rep 2002, 9:375-378.
36. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, et al.: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000, 11:1057-1059.
37. Lee Y, Lee CK: Classification of multiple cancer types by multicategory support vector machines using gene expression data. Bioinformatics 2003, 19:1132-1139.
38. Liu Y, Ringner M: Multiclass discovery in array data. BMC Bioinformatics 2004, 5:70.
39. Hartigan JA, Wong MA: A K-means clustering algorithm. Applied Statistics 1979, 28:100-108.
40. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
41. Kohonen T: Self-Organizing Maps 3rd edition. Berlin:Springer; 2001.
42. Nguyen DV, Rocke DM: Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 2002, 18:1625-1632.
43. Nguyen DV, Rocke DM: Multi-class cancer classification via partial least squares with gene expression profiles. Bioinformatics 2002, 18:1216-1226.
44. Perez-Enciso M, Tenenhaus M: Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum Genet 2003, 112:581-592.
45. Datta S: Exploring relationships in gene expressions: a partial least squares approach. Gene Expr 2001, 9:249-255.
46. Tan Y, Shi L, Tong W, Gene Hwang GT, Wang C: Multi-class tumor classification by discriminant partial least squares using microarray gene expression data and assessment of classification models. Comput Biol Chem 2004, 28:235-243.
47. Schleyer, et al.: PLS in Chemistry The Encyclopedia of Computational Chemistry, P.V.R. Chichester, UK: John Wiley & Sons; 2004.
48. Ellis M, Ballman K: Trawling for genes that predict response to breast cancer adjuvant therapy. J Clin Oncol 2004, 22:2267-2269.
49. Smith IE, Lipton L: Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001, 2:561-570.
50. Cleator S, Parton M, Dowsett M: The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002, 9:183-195.
51. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, et al.: Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003, 14:406-413.
52. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al.: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004, 40:205-211.
53. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003, 88:406-412.
54. Martin-Richard M, Munoz M, Albanell J, Colomo L, Bellet M, Rey MJ, et al.: Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 2004, 66:388-394.
55. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, et al.: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996, 74:1458-1465.
56. Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, et al.: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000, 6:3103-3110.
57. Ogston KN, Miller ID, Schofield AC, Spyrantis A, Pavlidou E, Sarkar TK, et al.: Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat 2004, 86:181-189.
58. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, et al.: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997, 3:593-600.
59. Prisack HB, Karreman Ch, Modlich O, Audretsch W, Rezai M, Bojar H: Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamid-based primary (radio-) chemotherapy. Anticancer Res. (accepted for publication in June, 2005).
60. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
61. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
62. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Natl Genet 2003, 33:49-54.
63. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, et al.: Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002, 11:863-872.
64. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
65. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L: Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 2005, 12:383-92.
66. Simon R, Radmacher MD, Dobbin K, McShane LM: pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003, 95:14-18.
67. Simon R, Radmacher MD, Dobbin K: Design of studies using DNA microarrays. Genet Epidemiol 2002, 23:21-36.
68. Ben-Dor A, Bruhn L, Friedman N, Nachman I, Schummer M, Yakhini Z: Tissue classification with gene expression profiles. J Comput Biol 2000, 7:559-83.
69. Ein-Dor L, Kela I, Getz G, Givol D, Domany E: Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2004, 21:171-178.